Study Impact and Key Takeaways
Sagar Lonial, MD, and Ellen Marin, PA-C, discuss the impact and key takeaways from their study as well as study limitations and future directions.
Study Conclusions and Its Implications
Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.
Patient Demographics and Study Results
Study results show that prophylactic tocilizumab reduces CRS incidence and severity in patients receiving teclistamab.
Background Information and Study Method
An overview of teclistamab in RRMM and the study methodology of using prophylactic tocilizumab to mitigate CRS associated with teclistamab
Overview of Cytokine Release Syndrome (CRS) and Its Management
Sagar Lonial, MD, and Ellen Marin, PA-C, discuss cytokine release syndrome (CRS) and the strategy to manage CRS in their clinic.
Overview of Relapsed or Refractory Multiple Myeloma (RRMM)
Sagar Lonial, MD, provides an overview of the currently available treatment options in relapsed/refractory multiple myeloma.